Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

Retinoblastoma, Recurrent Clinical Trial

— RTB  

Official title:

Phase I Study, Single Site, Open Label With Dose Escalation, for Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03284268
• Other study ID #: FSJD-RTB-2015
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 6, 2017
• Est. completion date: July 2024

Study information

• Verified date: April 2024
• Source: Fundació Sant Joan de Déu
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I study, single site, open label with dose escalation, for evaluate safety and the oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.

Description:

Phase I clinical trial, single-center, open-label, dose-escalation study, to evaluate the safety of the VCN-01 and, secondarily, its anti-tumoral activity. The trial sample consists of approximately 13 patients aged between 1 and 12 years old.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 13
• Est. completion date: July 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 12 Years

Eligibility

Inclusion Criteria:

1. Patients with retinoblastoma with a somatic mutation of the geneRB1 and active tumor in a single eye, or germinal mutation of RB1 with active tumor/s in an eye and the contralateral eye unaffected, enucleated or without tumor activity. In both cases, relapsed or refractory with the use of systemic, intraarterial or intravitreal chemotherapy or radiotherapy, in accordance with the availability at his/her referral site, in whom enucleation is the only recommended treatment under opinion of the medical team treating the case at the originating referral site.

2. Normal renal function: serum creatinine: <45µmol/L (0-2 years); <57µmol/L (3-6 years); <60µmol/L (7-10 years); <80µmol/L (11-13 years).

3. Normal Hepatic function: serum ALT: <0,52µkat/L (de 9 months -12 years); serum AST:

61-80 g/L (8 months - 5 years); 63-83 g/L (5-9 years); 63-82 g/L (9-12 years).

4. Adequate marrow reserve manifested in an absolute neutrophil count> 1000 / mm3, platelets> 100,000 / mm3 and hemoglobin> 8 g / dl, without transfusional or cytokine support at least one month prior to study entry.

5. Age greater than one year and less than 12 years at the time of inclusion in the study.

6. Informed consent form signed.

Exclusion Criteria:

1. Presence of factors that require immediate enucleation of the affected eye such as glaucoma, rubeosis iridis, anterior chamber involvement.

2. Comorbidities: Uncontrolled epilepsy with anticonvulsant treatment, cardiac disease not compensated by treatment.

3. Active Infections.

4. Other chronic or active acute diseases that under the criterion of the researcher were an exclusion criterion.

5. History of having received attenuated or live vaccines in the 30 days prior to inclusion in the study.

6. Any cause of Immunosuppression.

7. Trilateral Retinoblastoma.

8. Extraocular spread.

9. History of having received treatment for retinoblastoma with chemotherapy or radiation therapy by any means within 30 days prior to inclusion in the study.

10. Patients who can not complete the study procedures for reasons psychological or social.

11. Pregnancy. Female patients with procreative potential should be agree to undergo a blood or urine pregnancy test and the result should be negative to enter the study.

Related Conditions & MeSH terms

• Retinoblastoma
• Retinoblastoma, Recurrent

Intervention

Genetic:
• VCN-01
VCN-01 intravitreal injection

Locations

Country	Name	City	State
Spain	Hospital Sant Joan de Déu	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Sant Joan de Déu

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Histopathology of enucleated eyes after treatment with VCN-01	Presence of VCN-01 in vitreous humor samples of enucleated eyes	180 days
Primary	Incidence of Treatment-Emergent Adverse Events	The safety and tolerability of two intravitreal injections of VCN-01 will be determined with dose escalation until the maximum tolerated dose (MTD) is established based on the evaluation of adverse events and the observation of any dose-limiting toxicity (TLD).	180 days
Secondary	Tumor response	Tumor response rate (ORR) to VCN-01 at 28 days post-administration.	28 days
Secondary	VCN-01	Virus presence in blood samples, aqueous humor, ocular surface and nasal swabs, and its difference between the viral particles before and after the treatment to evaluate the excretion profile of the CNV-01.	180 days
Secondary	Immune response	The presence of neutralizing antibodies in blood samples in study patients to assess the immune response.	180 days